- Home
- CGCT vs EHAB Comparison
CGCT vs EHAB Comparison
Compare CGCT & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGCT
- EHAB
- Stock Information
- Founded
- CGCT 2024
- EHAB 2014
- Country
- CGCT United States
- EHAB United States
- Employees
- CGCT N/A
- EHAB N/A
- Industry
- CGCT
- EHAB Hospital/Nursing Management
- Sector
- CGCT
- EHAB Health Care
- Exchange
- CGCT NYSE
- EHAB Nasdaq
- Market Cap
- CGCT 345.0M
- EHAB 401.6M
- IPO Year
- CGCT 2025
- EHAB N/A
- Fundamental
- Price
- CGCT N/A
- EHAB $7.66
- Analyst Decision
- CGCT
- EHAB Buy
- Analyst Count
- CGCT 0
- EHAB 2
- Target Price
- CGCT N/A
- EHAB $8.75
- AVG Volume (30 Days)
- CGCT 101.8K
- EHAB 687.4K
- Earning Date
- CGCT 01-01-0001
- EHAB 08-05-2025
- Dividend Yield
- CGCT N/A
- EHAB N/A
- EPS Growth
- CGCT N/A
- EHAB N/A
- EPS
- CGCT N/A
- EHAB N/A
- Revenue
- CGCT N/A
- EHAB $1,032,300,000.00
- Revenue This Year
- CGCT N/A
- EHAB $4.66
- Revenue Next Year
- CGCT N/A
- EHAB $4.99
- P/E Ratio
- CGCT N/A
- EHAB N/A
- Revenue Growth
- CGCT N/A
- EHAB N/A
- 52 Week Low
- CGCT $10.00
- EHAB $6.85
- 52 Week High
- CGCT $11.16
- EHAB $10.91
- Technical
- Relative Strength Index (RSI)
- CGCT N/A
- EHAB 22.81
- Support Level
- CGCT N/A
- EHAB $9.06
- Resistance Level
- CGCT N/A
- EHAB $9.69
- Average True Range (ATR)
- CGCT 0.00
- EHAB 0.34
- MACD
- CGCT 0.00
- EHAB -0.26
- Stochastic Oscillator
- CGCT 0.00
- EHAB 6.61
About CGCT CARTESIAN GROWTH CORP III
Cartesian Growth Corp III is a blank check company.
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.